Drug Type ASO |
Synonyms duchenne muscular dystrophy therapeutics - Daiichi Sankyo/Orphan Disease Treatment Institute, ENA oligonucleotides, DS-5141 + [1] |
Target |
Mechanism DMD gene modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophies | Phase 2 | JP | 28 Jan 2016 | |
Muscular Dystrophy, Duchenne | Phase 2 | JP | 01 Oct 2015 |
Phase 1/2 | 8 | (All: DS-5141b 2.0 mg/kg) | knxweyooug(bosajbyyro) = hjpusfiwqd ofubkyvjhx (qyintndqjt, mytvmzdpfu - cxhuwsoeqp) View more | - | 07 Mar 2024 | ||
(All: DS-5141b 6.0 mg/kg) | knxweyooug(bosajbyyro) = vvwsqupovm ofubkyvjhx (qyintndqjt, yggdtxprbd - kfylzjtvdz) View more |